Vaxon Biotech - Articles and news items


Vaxon completes enrolment in Phase IIb trial of Vx-001 in NSCLC

Industry news / 16 March 2016 / Victoria White

Vx-001 is a therapeutic cancer vaccine based on proprietary antigens known as optimised cryptic tumour peptides…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...